| Literature DB >> 36102410 |
Paula Teixeira Lyra1, Ana Carla Augusto Moura Falcão1, Rafael Amora Cruz1, Antonio Victor Campos Coelho2, Edvaldo da Silva Souza1, Luiz Claudio Arraes de Alencar1, João Bosco Oliveira2.
Abstract
Gain-of-function mutations in the STAT1 gene have been initially associated with chronic mucocutaneous candidiasis. However, further research has shown that STAT1 GOF variants may increase susceptibility to infection by other intracellular pathogens. This report describes the first case of disseminated leishmaniasis associated with a STAT1 GOF mutation in a pediatric patient who did not have chronic mucocutaneous candidiasis. The patient was a four-year-old boy presenting with fever, severe asthenia, hepatosplenomegaly, pancytopenia, and liver failure. Bone marrow aspirate revealed hemophagocytosis and Leishmania parasites. Treatment consisted primarily of liposomal amphotericin B, as per the Hemophagocytic Lymphohistiocytosis 2004 protocol. After eight weeks of treatment, the patient did not improve and was submitted to diagnostic splenectomy. Activated macrophages and nodular spleen necrosis secondary to the visceral leishmaniasis were detected. Unfortunately, the patient died in the second week after splenectomy due to overwhelming systemic infection. DNA sequencing revealed a pathogenic (p. R274Q) GOF mutation in STAT1.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36102410 PMCID: PMC9444186 DOI: 10.31744/einstein_journal/2022RC0048
Source DB: PubMed Journal: Einstein (Sao Paulo) ISSN: 1679-4508
Laboratory workup
| Test | P1 | Reference range |
|---|---|---|
| Hemoglobin (g/dL) | 8.9 | |
| Hematocrit (%) | 26 | |
| Leukocytes (cells/mm3) | 2100 | |
| Neutrophils (%) | 19 | |
| Typical lymphocytes (%) | 60 | |
| Monocytes (%) | 18.6 | |
| Eosinophils (%) | 0.1 | |
| Basophils (%) | 2.7 | |
| Platelets (103/mL) | 86 | |
| Ferritin (ng/mL) | >1650 | 30-200 |
| Triglycerides (mg/dL) | 627 | |
| Fibrinogen (mg/dL) | 170 | 180-350 |
| Aspartate aminotransferase (U/L) | 882 | 0-35 |
| Alanine aminotransferase (U/L) | 308 | 0-35 |
| Total bilirubin (mg/dL) | 5.3 | 0.3-1.2 |
| Indirect bilirubin (mg/dL) | 4.9 | |
| Direct bilirubin (mg/dL) | 0.4 | 0-0.3 |
| Lactate dehydrogenase (U/L) | 6170 | 60-160 |
| Albumin (m/dL) | 1.4 | 3.5-5.4 |
| Alkaline phosphatase (U/L) | 968 | 36-150 |
| Amylase (U/L) | 223 | 25-125 |
| Soluble CD25 | Not measured | |
| NK cell activity | Not assessed | |
| IgA (mg/dL) | 190 | |
| IgG (mg/dL) | 1600 | |
| IgM (mg/dL) | 83 | |
| IgE (UI/L) | 148 | |
| Rubella IgG | Reactive | |
| HIV Serology | Non-reactive | |
| Immunophenotyping of lymphocytes | Not performed | |
| Rectal swab specimen culture | Multi-resistant | |
| Blood culture | Negative |
NK: natural killer; IgA: immunoglobulin A; IgG: immunoglobulin G; IgM: immunoglobulin M: IgE: immunoglobulin E.
Hemophagocytic lymphohistiocytosis (HLH-2004) diagnostic criteria
| Criteria | P1 |
|---|---|
| Clinical criteria | |
| Fever | Yes |
| Splenomegaly | Yes |
| Laboratory criteria | |
| Cytopenia (affecting two out of three cell populations) | Yes |
| Hypertriglyceridemia or hypofibrinogenemia | Yes |
| Hyperferritinemia >500 | Yes |
| Decreased or absent NK cell activity | Not assessed |
| Elevated soluble CD25 level (>2400 U/mL) | Not measured |
| Histopathological criteria | |
| Hemophagocytosis in bone marrow, spleen, or lymph nodes | Yes |
| No evidence of malignancy | Yes |
NK: natural killer.
Vaccines administered to the patient
| Vaccine | Primary doses + booster doses | Age (in months unless otherwise stated) |
|---|---|---|
| Bacillus Calmette-Guérin (BCG) | 1 | 1 day |
| Hepatitis B | 4 | 1 day, 1 and 6 |
| Diphtheria, pertussis, and tetanus (DPT) | 3 + 2 | 2, 4, 6, 15 and 48 |
| 3 | 2, 4 and 6 | |
| Oral polio | 3 + 1 | 2, 4, 6 and 15 |
| Oral human rotavirus | 2 | 2 and 4 |
| 10-valent pneumococcal conjugate (PCV10) | 3 + 1 | 2, 4, 6 and 12 |
| Meningococcal group C conjugate | 2 + 1 | 3, 5 and 15 |
| Measles, mumps, and rubella (MMR) | 2 | 12 and 48 |